Nicergoline increases serum substance P levels in patients with an ischaemic stroke

Cerebrovascular Diseases

Volumn 29, Issue 2, 2010, Pages 194-198

  Nishiyama, Yasuhiro ^a,b   Abe, Arata ^a,b   Ueda, Masayuki ^a   Katsura, Ken Ichiro ^a   Katayama, Yasuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Shioda Hospital   (Japan)

Author keywords

Aspiration pneumonia; Basal ganglia; Dysphagia; Ischaemic stroke; Nicergoline; Substance P

Indexed keywords

NICERGOLINE; SUBSTANCE P;

AGED; ARTICLE; ASPIRATION PNEUMONIA; BASAL GANGLION; BLOOD LEVEL; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STROKE PATIENT; SWALLOWING;

AGED; AGED, 80 AND OVER; BASAL GANGLIA; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM AGENTS; DEGLUTITION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NICERGOLINE; PNEUMONIA, ASPIRATION; RADIOIMMUNOASSAY; STROKE; SUBSTANCE P; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 72149116451     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000267279     Document Type: Article

References (20)

1. Sellars C, Bowie L, Bagg J, Sweeney MP, Miller H, Tilston J, Langhorne P, Stott DJ: Risk factors for chest infection in acute stroke: A prospective cohort study. Stroke 2007; 38: 2284-2291.
2. Nakagawa T, Sekizawa K, Arai H, Kikuchi R, Manabe K, Sasaki H: High incidence of pneumonia in elderly patients with basal ganglia infarction. Arch Intern Med 1997; 157: 321-324. (Pubitemid 27066402)
3. Vermeij FH, Scholte op Reimer WJ, de Man P, van Oostenbrugge RJ, Franke CL, de Jong G, de Kort PL, Dippel DW; Netherlands Stroke Survey Investigators: Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: data from the Netherlands Stroke Survey. Cerebrovasc Dis 2009; 27: 465-471.
4. Arai T, Yoshimi N, Fujiwara H, Sekizawa K: Serum substance P concentrations and silent aspiration in elderly patients with stroke. Neurology 2003; 61: 1625-1626. (Pubitemid 37505598)
5. Nakagawa T, Ohrui T, Sekizawa K, Sasaki H: Sputum substance P in aspiration pneumonia. Lancet 1995; 345: 1447.
6. Gerfen CR, McGinty JF, Young WS 3rd: Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci 1991; 11: 1016-1031.
7. McGinty JF: Co-localization of GABA with other neuroactive substances in the basal ganglia. Prog Brain Res 2007; 160: 273-284.
8. Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y: Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 2008; 26: 63-70.
9. Teramoto S, Yamamoto H, Yamaguchi Y, Ishii M, Hibi S, Kume H, Ouchi Y: Antiplatelet cilostazol, an inhibitor of type III phosphodiesterase, improves swallowing function in patients with a history of stroke. J Am Geriatr Soc 2008; 56: 1153-1154.
10. Yamaya M, Yanai M, Ohrui T, Arai H, Sekizawa K, Sasaki H: Antithrombotic therapy for prevention of pneumonia. J Am Geriatr Soc 2001; 49: 687-688.
11. Shinohara Y: Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. Cerebrovasc Dis 2006: 57-60.
12. Felisati G, Pignataro O, Di Girolamo A, Bruno E, Alessandrini M, Guidetti G, Monzani D, Beldi AM, Mira E, Benazzo M, Pallestrini E, Caligo G, Casani A, Battaglia A: Nicergoline in the treatment of dizziness in elderly patients. A review. Arch Gerontol Geriatr Suppl 2004; 9: 163-170.
13. Winblad B, Fioravanti M, Dolezal T, Logina I, Milanov IG, Popescu DC, Solomon A: Therapeutic use of nicergoline. Clin Drug Investig 2008; 28: 533-552.
14. Fioravanti M, Flicker L: Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001; 4:CD003159.
15. Joyce TJ, Yood RA, Carraway RE: Quantitation of substance-P and its metabolites in plasma and synovial fluid from patients with arthritis. J Clin Endocrinol Metab 1993; 77: 632-637.
16. Arai T, Yasuda Y, Takaya T, Toshima S, Kashiki Y: Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and symptomless dysphagia. Chest 2000; 117: 1819.
17. Arai T: ACE inhibitors and symptomless dysphagia. Lancet 1998; 352: 115-116.
18. Ohrui T: Preventive strategies for aspiration pneumonia in elderly disabled persons. Tohoku J Exp Med 2005; 207: 3-12.
19. Iwasaki H, Kajimura M, Osawa S, Kanaoka S, Furuta T, Ikuma M, Hishida A: A deficiency of gastric interstitial cells of Cajal accompanies by decreased expression of neuronal nitric oxide synthase and substance P in patients with type 2 diabetes mellitus. J Gastrotenterol 2006; 41: 1128-1130.
20. Li JY, Yong TY, Sebben R, Khoo E, Disney AP: Bilateral basal ganglia lesions in patients with end-stage diabetic nephropathy. Nephrology (Carlton) 2008; 13: 68-72.